In humans, 22q11.2 deletion syndrome (22q11DS) is considered the most common chromosome deletion syndrome. It is characterised by a clinical triad that includes congenital heart disease, hypocalcaemia and primary immunodeficiency. Approximately 85-90% of patients with this syndrome exhibit microdeletions in chromosome 22q11.2. Using congenital heart disease as a starting point, we designed a strategy for the screening and diagnosis of 22q11DS with an emphasis on immunological evaluation. A detailed clinical history and the subsequent quantitative and functional analyses of the lymphocyte subpopulations in the peripheral blood is crucial to classify as complete (<1%) or partial (95-99%) the disease and to guide clinicians in terms of patient isolation, vaccination, prophylaxis for opportunistic infections, use of irradiated blood products and immunological reconstitution. However, multidisciplinary care is necessary to detect and prevent long-term complications that could be severe, particularly in cases of complete 22q11DS.
CITATION STYLE
Vásquez-Echeverri, E., Sierra, F., Trujillo-Vargas, C. M., Orrego-Arango, J. C., Garcés-Samudio, C., Lince, R., & Franco, J. L. (2016). Immunological approaches to 22q11.2 deletion syndrome. Infectio. Elsevier Doyma. https://doi.org/10.1016/j.infect.2015.07.002
Mendeley helps you to discover research relevant for your work.